Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Videos | Coronavirus (COVID-19)

VIDEO: Video Game Helps Diagnose COVID-19 Patients and Manage Their Cardiac Complications

Eric Gantwerker, M.D., vice president and medical director at clinical video game simulator company Level Ex, and ...

November 12, 2020

Figure 1: PROTECT III found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29% reduction in MACCE at 90 days.

News | Hemodynamic Support Devices

Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization With Impella

November 12, 2020 — Abiomed recently announced new PROTECT III study data that demonstrates reduced rates of MACCE ...

November 12, 2020

Feature | AHA | Dave Fornell, Editor

American Heart Association 2020 Late-breaking Trial Presentations

Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual ...

November 20, 2020

Two of the top preforming pieces of content in October was the FDA clearance for the first indication for shortened DAPT for Medtronic's Resolute Onyx Drug Eluting Stent. A virtual tour of the new robotic electrophysiology lab at Banner Health led by Pete Weiss, M.D., also was among the most popular cardiology technology content.

Feature

November 2, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

November 02, 2020

Angiography with a co-registered view of pressure drops according iFR readings in a coronary vessel. The DEFINE PCI study showed patients had improved outcomes and less recurrent chest pain at one year using iFR physiologic measurements combined with landmarks shown on angiographic imaging to better guide therapy. Image by Philips Healthcare. #TCT #TCT2020 #TCTconnect

Feature | FFR Technologies | Dave Fornell, Editor

FFR Studies Find Several Surprises at TCT 2020

Fractional flow reserve (FFR) is considered the gold standard measure whether a coronary lesions needs a percutaneous ...

October 30, 2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Feature | TCT | Dave Fornell, Editor

Top 10 Takeaways on Interventional Technologies at TCT 2020

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

October 29, 2020

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe.

Feature | Magnetic Resonance Imaging (MRI)

Cardiac MRI Contrast Agents Carry Low Risk of Adverse Events

October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a very ...

October 29, 2020

The Watchman FLX will be tested in the CHAMPION-AF trial looks at next-generation transcatheter LAA device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation.

News | Atrial Fibrillation

Boston Scientific Initiates Trial to Evaluate Watchman FLX LAA Closure Device as First-Line Treatment

Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the ...

October 29, 2020

Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system. #TCT2020 #TCTconnect

News | Pulmonary Embolism

Acute Hemodynamic Improvement With Percutaneous Mechanical Thrombectomy in a Real-world Pulmonary Embolism Population

October 23, 2020 — Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world p ...

October 23, 2020

Fractional Flow reserve (FFR) selection on the Abbott, St. Jude FFR system console. The TARGET FFR study at #TCT2020 #TCTconnect.

News | FFR Technologies

FFR-guided PCI Optimization Strategy May Lead to Improved Outcomes

October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided ...

October 23, 2020

An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone actually was not flow limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings. #TCT2020 #TCTconnect

News | FFR Technologies | Dave Fornell, Editor

FFR-CT Did Not Significantly Reduce Costs But Reduced Rates of Invasive Coronary Angiography

October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from ...

October 22, 2020

Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect

Feature | Stents | Dave Fornell, Editor

Durable Polymer Drug-Eluting Stents Perform Better Than Biodegradable Polymer DES

October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable ...

October 22, 2020

For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020

News | Stents

Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-inferiority for Thrombotic Events

October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology ...

October 22, 2020

Videos | Cath Lab

VIDEO: Intravascular Lithotripsy to Treat Severely Calcified Coronary Artery Lesions

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

October 19, 2020

Videos | Stents Drug Eluting

VIDEO: Results of the OPTIMIZE IDE Trial for the Svelte Drug Eluting Stent

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

October 19, 2020